Floatz logo

Orantinib

Hepatocellular Carcinoma

Taiho Pharmaceutical Co., Ltd.Phase 3Dormant
B
56/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
52/ 100
Competitive Position
65/ 100

Competitive context

521 Active assets in the Hepatocellular Carcinoma cohort.

Asset / SponsorPhaseRating
Adefovir
Bukwang Pharmaceutical
Phase 4BBB
Huaier Granule
Tongji Hospital
Phase 4BBB
Sorafenib
Bayer
Phase 4BBB
Carboplatin
AstraZeneca
Phase 4BB
Theprubicin
RWTH Aachen University
Phase 4BB

View all 50 →

Same molecule, other indications

Orantinib is also rated in:

cancer of unknown primary siteDormant
CC
Indicative ·
46 / 100
View asset →
plasma cell myelomaDormant
CC
Indicative ·
43 / 100
View asset →
kidney cancerDormant
C
Indicative ·
39 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →